Evorpacept

5 trials 2 recruiting Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

3 Completed trials

2 Sponsors

10 Countries

Phase II/III

Phase II

Phase I/II

Phase II/III: 1 Phase II: 3 Phase I/II: 1

Indications tested

Head and neck cancer 2 Squamous cell carcinoma of head and neck 2 Squamous cell carcinoma 2 Plasma cell myeloma refractory 1

Sponsors using this IMP

Alx Oncology Inc. 4 Sanofi-Aventis Recherche & Developpement 1

All trials

5 total

A Study of Evorpacept (ALX148) in Patients with Metastatic HER2-Positive Breast Cancer Recruiting

2025-522012-16-00 Phase II 3 countries Alx Oncology Holdings Inc.
Isatuximab in combination with evorpacept and dexamethasone in RRMM Recruiting

2024-514993-38-00 Phase I/II 6 countries Sanofi-Aventis Recherche & Developpement
A Study of Evorpacept (ALX148) in Patients with Advanced Gastric Cancer Ended

2023-509406-30-00 Phase II/III 5 countries Alx Oncology Inc.
A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) Ended

2023-508340-22-00 Phase II 3 countries Alx Oncology Inc.
A Phase 2 study of ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma… Ended

2023-508342-17-00 Phase II 3 countries Alx Oncology Inc.

Showing 1–5 of 5 trials

← All drugs A–Z